Development and Validation of a Predictive Model for Occult Liver Metastasis in Pancreatic Ductal Adenocarcinoma Using Subjective Imaging and Clinical Data

利用主观影像和临床数据建立和验证胰腺导管腺癌隐匿性肝转移预测模型

阅读:1

Abstract

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is highly lethal, with liver metastases leading to poorer outcomes. Occult liver metastases (OLM), undetected by initial imaging, complicate treatment and diminish survival rates. We aimed to develop and validate a predictive model for occult liver metastasis in pancreatic cancer, which is crucial for effective preoperative planning. METHODS: A total of 142 patients with PDAC were retrospectively analyzed between January 1, 2020, and December 31, 2023. Malignant cases were confirmed by pathology, and benign cases were confirmed by pathology or follow-up. Patients were randomly divided into training and validation cohorts at a ratio of 7:3. Factors associated with OLM in PDAC were identified using a stepwise approach, beginning with univariate and followed by multivariate logistic regression analyses. Logistic regression was used to develop clinical, radiological, and combined models, with performance evaluated using the area under the curve (AUC). A nomogram was constructed, and calibration and decision curves were generated. Additionally, machine learning models (RF, SVM, XGBoost) were employed, with AUC and variable importance plots used to evaluate their performance. RESULTS: Two clinical and four radiological features independently predicted OLM. The combined model achieved an AUC of 0.86 (training) and 0.84 (validation), outperforming clinical (AUC: 0.73, 0.75) and radiological models (AUC: 0.81, 0.75). Machine learning models showed AUCs of 0.787 (RF), 0.850 (SVM), and 0.851 (XGBoost) in the validation cohort. Decision and calibration curves confirmed the combined model's reliability and clinical utility. CONCLUSION: The combined model incorporating clinical and radiological features offers a simple, cost-effective tool to identify PDAC patients at high risk for OLMs, supporting informed surgical decisions and improved outcomes. Integrating clinical and radiological markers enhances early detection and personalized care in PDAC management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。